Hugel, a leading Korean medical aesthetics company, has set its sights on China’s high – end dermocosmetics sector with the launch of its premium brand BYRYZN BR. This move is part of the company’s broader strategy to expand across Asia, capitalizing on the growing demand for advanced anti – aging and skincare solutions.
On Monday, Hugel officially introduced the BYRYZN BR Botuligin Capture EX Ampoule in China. This product is a customized version of the existing Botuligin Capture Ampoule, specifically formulated to target wrinkles in three crucial areas: nasolabial folds, the fine lines around the eyes, and forehead expression lines. The launch of this initial product is just the beginning, as four more products from the BYRYZN BR line are scheduled to be released in phases. These upcoming products will focus on aspects such as hydration, lipid barrier support, and enhancing skin elasticity.
The BYRYZN BR brand, which made its debut in Korea in April 2024, owes its efficacy to Hugel’s proprietary ingredients, including TARGET HA, Botuligin, and H.ECM. It is designed to provide comprehensive anti – aging care, covering hydration, wrinkle reduction, and skin barrier reinforcement. To commemorate the China launch, Hugel organized an event at the InterContinental hotel in Hangzhou, attracting approximately 250 attendees. The guest list included members of the China Anti – Aging Association, surgeons, and med – aesthetics specialists. A Hugel spokesperson stated, “With our entry into the Chinese market, BYRYZN BR marks a new global milestone following successful expansion into North America, Southeast Asia, and Northeast Asia. We aim to actively promote BYRYZN BR to meet the needs of China’s discerning dermocosmetic consumers,” highlighting the company’s high hopes for its new venture in China.
- Tori Spelling Admits She Looks “Completely Different“
- Sarah Huckabee Sanders Exposes Ivanka Trump’s Plastic Surgery Rumors
- Doja Cat’S Plastic Surgery Disaster: Asks Fans Not To Notice
